Provention Bio Reports Third Quarter 2019 Financial Results

- PRV-031 (teplizumab) Granted Breakthrough Therapy and PRIME Designations – - Meeting with FDA for PRV-031 (Teplizumab) Scheduled for Fourth Quarter 2019; BLA Submission Targeted for Fourth Quarter 2020 – - Strong Cash Balance of $95.1 Million as of September 30, 2019 -

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here